Crossmark

Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study

Crossref DOI link: https://doi.org/10.1016/j.ad.2025.104531

Published Print: 2026-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Mansilla-Polo, M. https://orcid.org/0000-0001-6730-6723
Pons-Benavent, M.

Fernández-Crehuet, P.

Vilarrasa, E.

Albanell-Fernández, C.

Morales-Tedone, E.

Rausell-Félix, F.

Alcalá-García, R.

Matellanes-Palacios, M.

Martín-Ezquerra, G.

Alfageme, F.

Ciudad-Blanco, C.

López-Villaescusa, M.T.

Segura-Palacios, J.M.

Pascual-Ramírez, J.C.

Fernández-Díaz, M.L.

Falkenhain-López, D.

García-Gil, M.

Agustí-Mejías, A.

No-Pérez, N.

Naranjo-Guerrero, N.

Estenaga-Pérez, Á.

García-Ruiz, R.

Mahiques-Santos, L.

Garbayo-Salmons, P.

Martorell, A.

Escutia-Muñoz, B.

Martín-Torregrosa, D.

Cuenca-Barrales, C.

Paniego, C. Ureña

Botella-Estrada, R.

Molina-Leyva, A.
License Information

Text and Data Mining valid from 2026-03-01

Text and Data Mining valid from 2026-03-01

Version of Record valid from 2025-12-04
More Information

This article is maintained by: Elsevier

Article Title: Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study

Journal Title: Actas Dermo-Sifiliográficas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ad.2025.104531

Content Type: article

Copyright: © 2025 AEDV. Published by Elsevier España, S.L.U.